Company profile for Magnus Medical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a privately held medical device company developing a novel, rapid-acting brain stimulation technology designed to treat people suffering from major depressive disorder (MDD) who have not responded to existing treatments. RESTORING MENTAL HEALTH. Depression is caused by identifiable changes in brain networks. We can restore healthy neural activity and relieve symptoms of depression. Our mission is to restore and susta...
We are a privately held medical device company developing a novel, rapid-acting brain stimulation technology designed to treat people suffering from major depressive disorder (MDD) who have not responded to existing treatments. RESTORING MENTAL HEALTH. Depression is caused by identifiable changes in brain networks. We can restore healthy neural activity and relieve symptoms of depression. Our mission is to restore and sustain mental health.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1350 Old Bayshore Highway Suite 600 Burlingame CA 94010
Telephone
Telephone
(415) 231-7407
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251124582323/en/Magnus-Medical-Announces-Uninterrupted-2026-Payment-Stability-for-SAINT-Neuromodulation-in-CMS-OPPS-Final-Rule

BUSINESSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2024/06/12/2897293/0/en/Insider-Information-Nexstim-Plc-Provides-Further-Details-on-Technology-License-Agreement-with-Magnus-Medical-Inc.html

GLOBENEWSWIRE
12 Jun 2024

https://www.businesswire.com/news/home/20230515005061/en

BUSINESSWIRE
15 May 2023

https://news.cision.com/selectimmune/r/magnus-nylen-proposed-as-new-member-of-the-selectimmune-pharma-board,c3665713

CISION
11 Nov 2022

https://www.businesswire.com/news/home/20220906005228/en

BUSINESSWIRE
06 Sep 2022
FDA canonizes Saint neurostim system for severe depression
FDA canonizes Saint neurostim system for severe depression

06 Sep 2022

// Andrea Park FIERCEBIOTECH

https://www.fiercebiotech.com/medtech/fda-canonizes-magnus-medicals-saint-neuromodulation-system-treat-severe-depression

Andrea Park FIERCEBIOTECH
06 Sep 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty